Elevar & Relay Therapeutics`s Lirafugratinib Licensing for Cancer
03 Dec 2024 //
GLOBENEWSWIRE
Lirafugratinib Elicits Durable Responses Across Several FGFR2+ Solid Tumors
13 Oct 2023 //
ONCLIVE
Relay Therapeutics Announces RLY-4008 Data Showing Durable Responses Across Multiple FGFR2-Altered Solid Tumors
12 Oct 2023 //
GLOBENEWSWIRE